Street Calls of the Week
Investing.com - Jefferies has initiated coverage on PolyPeptide Group AG (SIX:PPGN) with a Buy rating and a price target of CHF38.70.
The research firm views PolyPeptide as a quality peptide contract development and manufacturing organization (CDMO) that is currently undervalued in the market despite its strong technical capabilities and flexible manufacturing platform.
Jefferies notes that PolyPeptide trades at a discount despite having underwritten mid-term guidance, suggesting the current valuation implies growth materially below company guidance for 2024-2028.
The firm sees "compelling upside potential" for PolyPeptide stock should the company deliver on its targets over the coming years.
The CHF38.70 price target established by Jefferies represents significant potential appreciation from current trading levels for the Swiss-listed pharmaceutical manufacturing company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
